The DOI matches its Crossref record; 85 of the 86 references it cites were found in a registry or an index.
Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans
Open accessAbstract
Studies in animals have documented that, compared with glucose, dietary fructose induces dyslipidemia and insulin resistance. To assess the relative effects of these dietary sugars during sustained consumption in humans, overweight and obese subjects consumed glucose- or fructose-sweetened beverages providing 25% of energy requirements for 10 weeks. Although both groups exhibited similar weight gain during the intervention, visceral adipose volume was significantly increased only in subjects consuming fructose. Fasting plasma triglyceride concentrations increased by approximately 10% during 10 weeks of glucose consumption but not after fructose consumption. In contrast, hepatic de novo lipogenesis (DNL) and the 23-hour postprandial triglyceride AUC were increased specifically during fructose consumption. Similarly, markers of altered lipid metabolism and lipoprotein remodeling, including fasting apoB, LDL, small dense LDL, oxidized LDL, and postprandial concentrations of remnant-like particle-triglyceride and -cholesterol significantly increased during fructose but not glucose consumption. In addition, fasting plasma glucose and insulin levels increased and insulin sensitivity decreased in subjects consuming fructose but not in those consuming glucose. These data suggest that dietary fructose specifically increases DNL, promotes dyslipidemia, decreases insulin sensitivity, and increases visceral adiposity in overweight/obese adults.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Habitual consumption of significant amounts ( . 10% energy) of dietary fructose contributes to TG elevations, particularly in people with HTG.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [158]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The impact of fructose/sucrose intake on HDL-C does not seem different from that of other refined carbohydrates.158,159”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [158]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Sucrose, a disaccharidecontaining glucose and fructose, represents an important source of fructose in the diet. 158,175”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [158]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Fructose has emerged as a potent activator of carbohydrate response element-binding protein (ChREBP), which is particularly relevant in the context of MASLD, given the global rise in fructose consumption that parallels the increasing prevalence of MASLD [78- 82].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [81]
Experimental — accuracy not yet measuredIn the citing paper
“dietary fructose contributes to TG elevations; these effects are dose dependent and become clinically relevant when the intake is .10%energy daily-with a habitual fructose consumption between 15 and 20% of the energy intake, plasma TG increases as much as 30 -40%.”
From ESC/EAS Guidelines for the management of dyslipidaemias (2011) · cites this paper as [76]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Follow-up report on the diagnosis of diabetes mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2003) · Diabetes Care · doi:10.2337/diacare.26.11.3160 · Cited by 3,784
A new predictive equation for resting energy expenditure in healthy individuals
Mifflin, M., St Jeor, S., Hill, L., Scott, B., Daugherty, S., & Koh, Y. (1990) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/51.2.241 · Cited by 2,544 · cited 1×
“calculated by the Mifflin equation (67), with an adjustment of 1.”
MethodNordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058
Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women
Bansal, S., Buring, J. E., Rifai, N., Mora, S., Sacks, F. M., & Ridker, P. M. (2007) · JAMA · doi:10.1001/jama.298.3.309 · Cited by 1,619
Yu, C., Chen, Y., Cline, G. W., Zhang, D., Zong, H., Wang, Y., Bergeron, R., Kim, J. K., Cushman, S. W., Cooney, G. J., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200958200 · Cited by 1,561 · cited 1×
“Diacylglycerol is a known activator of novel PKC (51), and increases of both diacylglycerol and novel PKC activity are associated with lipid-induced insulin resistance (52, 53).”
BackgroundItani, S. I., Ruderman, N. B., Schmieder, F., & Boden, G. (2002) · Diabetes · doi:10.2337/diabetes.51.7.2005 · Cited by 1,390
Lipoprotein lipase: structure, function, regulation, and role in disease
Mead, J., Irvine, S., & Ramji, D. (2002) · Journal of Molecular Medicine · doi:10.1007/s00109-002-0384-9 · Cited by 927
Metabolic origins and clinical significance of LDL heterogeneity
Berneis, K. K., & Krauss, R. M. (2002) · Journal of Lipid Research · doi:10.1194/jlr.r200004-jlr200 · Cited by 896
Self-citationMorino, K., Petersen, K. F., & Shulman, G. I. (2006) · Diabetes · doi:10.2337/db06-s002 · Cited by 853
Conway, J. M., Ingwersen, L. A., Vinyard, B. T., & Moshfegh, A. J. (2003) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/77.5.1171 · Cited by 820
Research works printed but not linked: 3
- Herman, 1970, Fed. Proc., 29, 1302
- Schwarz, 1993, Diabetes., 42, A39
- Teff, 2009, J. Clin. Endocrinol. Metab.
Cited by
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
Pathophysiology of human visceral obesity: an update
Tchernof, A., & Després, J.-P. (2013) · Physiological Reviews · doi:10.1152/physrev.00033.2011 · Cited by 2,583
Metadata
- Authors
- Stanhope, K. L., Schwarz, J. M., Keim, N. L., Griffen, S. C., Bremer, A. A., Graham, J. L., Hatcher, B., Cox, C. L., Dyachenko, A., Zhang, W., McGahan, J. P., Seibert, A., Krauss, R. M., Chiu, S., Schaefer, E. J., Ai, M., Otokozawa, S., Nakajima, K., Nakano, T., Beysen, C., Hellerstein, M. K., Berglund, L., & Havel, P. J.
- Affiliations
- University of California, Davis (US)
- University of California, San Francisco (US)
- United States Department of Agriculture (US)
- Touro University California (US)
- UCSF Benioff Children's Hospital (US)
- Tufts University (US)
- KineMed (United States) (US)
- VA Northern California Health Care System (US)
- Corresponding author
- Havel, Peter J.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2009-05-01
- Volume
- 119
- Issue
- 5
- Pages
- 1322-1334
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC2673878
- OpenAlex
- W2146966453
- Cited by
- 1,765
- References
- 86
- Citations by year
- 2026: 56 · 2025: 73 · 2024: 56 · 2023: 96 · 2022: 92 · 2021: 101 · 2020: 113 · 2019: 112 · 2018: 135 · 2017: 105 · 2016: 118 · 2015: 121 · 2014: 135 · 2013: 143 · 2012: 108
- FWCI
- 74.06
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- American Diabetes Association (UL1 RR024146)
- U.S. Department of Agriculture (5306‐51530‐016‐00D, UL1 RR024146)
- Bristol-Myers Squibb
- Pfizer
- Sanofi
- American College of Radiology Imaging Network
- School of Veterinary Medicine, University of California, Davis
- KineMed
- Novo Nordisk
- Otsuka Pharmaceutical
- National Institutes of Health (AT‐003545, 5r01hl075675-05, 5r01hl091333-02, HL‐091333, R01 HL-075675, HL‐075675, RR024146)
- University of California, Davis (95616, RR024146, UL1 RR024146)
- Agricultural Research Service (5306‐51530‐016‐00D)
- National Heart, Lung, and Blood Institute (R01 HL-075675, R01 HL-091333, HL-091333, R01HL107256)
- National Center for Research Resources (RR-024146, 5306-51530-016-00D, UL1RR024146)
- National Center for Complementary and Integrative Health (AT0-02993, AT0-03545, AT 002599, R21AT002993, R21AT002599)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diet, Metabolism, and Disease
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- dietary fructose, glucose, visceral fat, insulin resistance, insulin sensitivity, dyslipidemia, hepatic de novo lipogenesis, triglycerides, lipoprotein remodeling, oxidized LDL, remnant-like particles, overweight and obesity, weight gain
- MeSH terms
- Beverages, Blood Glucose, Body Weight, Energy Intake, Double-Blind Method, Eating, Female, Fructose, Glucose, Humans, Insulin, Insulin Resistance, Lipids, Lipoproteins, Liver, Male, Middle Aged, Models, Biological, Obesity, Sex Characteristics, Triglycerides, Gene Expression, Dietary Sucrose, Subcutaneous Fat, Intra-Abdominal Fat, Overweight, Lipid Metabolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. https://app.cochat.ai/papers/10.1172/jci37385
- The paper
- Stanhope, K. L., Schwarz, J. M., Keim, N. L., Griffen, S. C., Bremer, A. A., Graham, J. L., Hatcher, B., Cox, C. L., Dyachenko, A., Zhang, W., McGahan, J. P., Seibert, A., Krauss, R. M., Chiu, S., Schaefer, E. J., Ai, M., Otokozawa, S., Nakajima, K., Nakano, T., . . . Havel, P. J. (2009). Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. Journal of Clinical Investigation. https://doi.org/10.1172/jci37385
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.